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The global burden of breast cancer (BC) is increasing significantly. This trend is caused by 
several factors such as late diagnosis, limited treatment options for certain BC subtypes, drug 
resistance which all lead to poor clinical outcomes. Recent research has reported the role of 
epigenetic alterations in the mechanism of BC pathogenesis and its hallmarks include drug 
resistance and stemness features. The understanding of these modifications and their significance 
in the management of BC carcinogenesis is challenging and requires further attention. 
Nevertheless, it promises to provide novel insight needed for utilizing these alterations as potential 
diagnostic, prognostic markers, predict treatment efficacy, as well as therapeutic agents. This 
highlights the importance of continuing research development to further advance the existing 
knowledge on epigenetics and BC carcinogenesis to overcome the current challenges. Hence, this 
review aims to shed light and discuss the current state of epigenetics research in the diagnosis and 
management of BC. 




























Cancer is a significant global health concern. In 2018, an estimate of 18.1 million new individuals 
were diagnosed with cancer alongside 9.6 million mortalities [1]. By 2040, these numbers are 
expected to double, particularly in low and middle-income countries. Consequently, the burden of 
cancer on healthcare systems is likely to immensely increase worldwide [2]. This highlights the 
need for more research to further advance an early and rapid detection and management of this 
disease which serve as a key role of improving survival rates and patient-centered cancer care [3].  
Breast Cancer (BC) is one of the most common diagnosed female cancers and leading cause of 
cancer death among women, accounting for an estimate of 627,000 (6.6%) deaths worldwide [4]. 
Since 2008, BC incidence and mortality rates have increased globally by more than 20% and 14% 
respectively. The global BC burden is estimated to have risen to 2.1 million new cases in 2018 
compared to nearly 1.7 million in 2012 [1, 5].  
The high incidence and death rates in BC are linked to various factors, among which the most 
common being its heterogeneous nature. The inter/intra-tumoral heterogeneity, usually affecting 
one anatomic site of the breast with phenotypic and molecular diversity, plays a key role in its 
histology and staging [6]. The molecular stratification of BC is primarily based on gene expression 
profiling; this also includes the expression status of hormonal receptors, such as the estrogen 
receptor (ER) and progesterone receptor (PR), as well as human epidermal growth factor receptor 
2 (HER2) which is also known as ERBB2, and proliferation index (Ki-67). Based on this, BC is 
classified into five subtypes, including luminal ER positive (luminal A and luminal B), HER2 
enriched, normal like and triple negative receptors (basal like) (Fig. 1) [6,7].  
Additional molecular subtypes were recently identified to include claudin low and molecular 
apocrine. This molecular sub-classification has served as a guiding principle for the utility of 
targeted therapies such as poly ADP ribose polymerase (PARP) inhibitors, HER2-targeted agents 
(e.g., Trastuzumab) and endocrine therapy (e.g., Tamoxifen), leading to better outcomes and 











Figure 1. Breast cancer classification 
 
Anticancer drug resistance is one of the major challenges in the management and treatment of 
advanced BC which can be caused by intrinsic and acquired factors that alter molecular/signaling 
pathways leading to poor survival [8]. Among these factors are tumor heterogeneity, genomic 
instability, self-renewing cancer stem cells (CSC), tumor microenvironment via direct interplay of 
extracellular matrix, growth factors, cytokines and stromal cells and epigenetic 
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Figure 2. Chemoresistance in cancer 
 
Epigenetic modifications are an area of major interest as they play a role in overexpression of 
oncogenes or silencing of tumor suppressor genes, consequently stimulating tumorigenic pathways 
and affecting therapeutics in BC [13, 14]. In this review, we aim to cover the general mechanisms 
of epigenetics, epigenetic deregulation in BC, drug resistance, association of epigenetics with poor 
clinical outcome and role of epigenetic biomarkers in diagnostics and therapeutics. 
2: Epigenetic mechanisms 
Epigenetics is a heritable molecular mechanism, controlled by external factors, that regulates genes 
expression without altering the actual sequence of DNA [15]. Progression of BC involves the 
accretion of aberrant changes both at genetic and epigenetic levels which ultimately lead to 
tumorigenesis. Therefore, epigenetic regulations caused by DNA methylation, histone 
modification, nucleosome remodeling, and RNA-mediated gene targeting, are known to modulate 
a number of molecular, cellular and biological pathways associated with breast carcinogenesis 
[16]. Recent findings indicate the role of epigenetic deregulations in BC hallmarks including drug 
resistance and stemness features [17]. Herein we elucidate the main molecular mechanisms of 
epigenetics and how epigenetic changes contribute into BC pathogenesis including the genetic 
reprogramming of oncogenes and tumor suppressor genes.  
2.1: DNA methylation 
DNA methylation is a critical enzyme-driven chemical modification where a methyl group is 
added covalently to cytosine or adenine in DNA sequence by a family of DNA methyltransferases 
(DNTMs) enzymes (DNMT1, DNMT3A, and DNMT3B) [18]. The already methylated DNA is 
maintained by DNMT1, while de novo methylation is carried out by DNMT3A and DNMT3B 









significant processes including transcription, post transcription, post translation, remodeling of 
chromatin, imprinting of genome, inactivation of X-chromosome and suppression of repeated 
elements of DNA [20, 21].  
As a result of methylation, certain gene regulator proteins are explicitly attached to DNA and 
restrict the transcription factors from accessing to chromatin which affects gene expression. Once 
the regulator sequences in the genes are altered, the transcription factors will no longer be able to 
identify them. Additionally, DNA methylation sets up a closed and restrictive chromatin form, 
making the modified chromatin unresponsive to nuclease digestion leading to reduced acetylation 
of histone proteins on the chromatin. Contrarily, intragenic regions, which control elongation of 
transcription and alternative splicing, have been found to have enhanced DNA methylation [22].  
In vertebrate genome, CpG-rich regions, known as CpG islands, such as promoter regions, 
transcription start sites, and repetitive sequences are not generally methylated. Most of the genome 
is not GC rich and subsequently is highly methylated which is required for chromosomal stability 
[23]. In this way, hypomethylation and hypermethylation can happen simultaneously relying on 
the genome region and can thus influence the disease outcomes. Genome wide loss of DNA 
methylation i.e. hypomethylation is reported in various tumors and has been reported to have an 
impact on genome stability, DNA damage, and rejuvenation of retroviruses/transposons [20, 24, 
25]. 
An aberrant DNA methylation, caused by endogenous and exogenous mutagenic processes, 
usually occurs in the CpG-rich regions of gene promoters contributing to the expression of proto-
oncogenes or silencing of tumor suppressor genes (Fig. 3) [26]. Hence, carcinogenesis and 
metastasis are associated with loss of methylation in proto-oncogenes and turning on of 










Figure 3. Schematic showing methylation of CpG island and histone modifications causing 
deregulation of oncogenes and tumor suppressor genes  
 
Furthermore, genome wide loss of methylation may cause loss of imprinting which plays a role in 
the early stages of transformation and tumorigenesis. For instance, insulin-like growth factor-2 
(IGF2) plays a role in cell growth while loss of imprinting in IGF2 results in upregulation and 
instability of genome wide chromatin [29]. On the other hand, progression to malignancy and DNA 
hypomethylation are frequently related to mutations in DNMTs [30]. Downregulation of tumor 
suppressor genes such as BCL2, BRCA1, RAS and hypermethylation occurs in numerous 
neoplastic cells thus boosting malignant transformation [31].  
Dysregulated methylation of genes and regulatory proteins has now become more evident in the 
pathogenesis of human cancers including BC. Accordingly, methylation-analysis assays are 
currently used in research aiming to develop novel diagnostic and therapeutic strategies of BC as 
evidenced in various studies [32-34]. There have been various underlying mechanisms explored 
as to how DNA methylation triggers cancer pathogenesis. For instance; the hypomethylation of 
SEPTIN7, TRIM27, LIMD2 and LDHA, have been associated with BC metastasis, invasion and 
proliferation [33]. Also, it has been reported that APC, RARB, GSTP1, DAPK, and SFN genes 
are frequently methylated in BC cases [34]. Moreover, methylation induced aberrant expression 
of Claudin-6 (CLDN6) triggers breast carcinogenesis by recruiting MeCP2, deacetylating H3 and 
H4, and altering chromatin structure [35].  
Dysregulated methylation of DNA is an important reversible epigenetic mechanism associated 
with BC pathogenesis via deregulated expression of genes. These genes are critical in the 
development of clinicopathological features such as tumor stage, histological grade, and TP53 
status [36]. There are a number of reports showing how deregulated DNA methylation triggers 
altered gene expression converging towards the development of clinicopathological features of BC 
and hence have great diagnostic and therapeutic potential [37-39]. For instance, the epigenetic 
silencing of SFRP1 has been directly linked with poor prognosis in BC [36]. 
It has been observed that menopause accelerates epigenetic age-related diseases including cancer. 
Recently, a methylome based study reported that the accumulation of DNA methylation increased 
the susceptibility to develop postmenopausal BC. This underlines the importance of using these 
alterations as diagnostic biomarkers [40].  
Aberrant epigenetic modifications of antioxidant gene expression have also been well studied and 
show an association with BC development and therapeutic challenges. Griess et al., reported a 
negative correlation of promoter DNA methylation and down-regulation of superoxide dismutase 
3 (SOD3) expression in BC. The low expression/deletion of SOD3 gene is associated with more 
aggressive subtypes (TNBC and Her2+) and consequently poor clinical outcome in BC patients 
[41]. Hence, epigenetic silencing of SOD3 caused by differential methylation of CpG sites of the 
SOD3 gene may serve as a foundation for the use of epigenetic modifiers molecules in novel anti-
cancer therapy strategies. 
It is well documented that TNBC have widespread genome-wide hypomethylation compared to 
other BC subtypes. In 2018, Good et al showed that the expression of Ten-eleven translocation 









prognosis in TNBC. Additionally, TET1 is an oncogene that promotes oncogenesis through its 
abnormal hypomethylation by activating various signaling pathways including PI3K-mTOR. 
Hence, this may identify TET1 as a potential therapeutic target for TNBC [42]. Another study 
reported that the differential methylation status, gene expression and pathways activation are 
associated with the development of chemotherapy resistance to docetaxel in TNBC [43]. 
Noteworthy, aberrant DNA methylation is also critical in cancer stemness features. Recently, a 
comprehensive genome-wide analysis of DNA-methylation demonstrated that clustering of 
circulating tumor cells (CTCs) induces metastasis and progression in BC. This is caused by 
deregulated methylation binding sites for stemness and proliferation-associated transcription 
factors including OCT4, NANOG, SOX2, and SIN3A. This indicates that cluster-targeting has 
potential to inhibit metastasis and thus may be of therapeutic importance [44]. Furthermore, 
deregulated DNA methylation of homeobox C8 (HOXC8) gene, a master regulator of cell fate 
during embryonic development, reduces its expression in BC stem/progenitor cells and promotes 
stemness features [45]. Worner et.al. suggested that deregulated DNA methylation is one of the 
critical underlying events associated with transformation of the mesenchymal stem cells into 
tumor-forming cells in BC development [46].  
It has also been shown that DNA methylation and other epigenetic processes play a vital role in 
regulating the expression and functioning of non-coding RNAs (ncRNAs), which are critical in 
maintaining the biological homeostasis. Alterations in these mechanisms lead to aberrant 
expression of ncRNA favoring BC pathogenesis. Interestingly, a recent study by Shi et al. 
investigated the epigenetic silenced miR-133a-3p and reported its correlation with BC metastasis 
and stemness features via upregulating mastermind-like transcriptional coactivator 1 (MAML1) 
[47]. Also, it has been revealed that the aberrant DNA methylation of the tumor suppressor 
microRNA-874 promotes breast carcinogenesis and is associated with lymph node metastasis [48]. 
Another investigation revealed that aberrant DNA methylation lead to BC pathogenesis via 
dysregulation of 12 ncRNAs including; miRNA124, 125b, 127, 132, 137, 148a, 191, 193a, 203, 
34b, 375, 9 [49]. Thus, these alterations might serve as a prognostic biomarker, and therapy targets.  
Drug resistance in BC cells due to reprogramming of epigenetic and genetic regulatory 
mechanisms poses a huge challenge for effective cancer therapy. Here we have included some of 
the recent findings on how deregulated methylation status of various genes related to cell growth 
and survival converge towards drug resistance in BC. An interesting finding revealed that 
remodeling and reprogramming of 3D epigenome are the central regulatory underlying 
mechanisms of endocrine resistance in ER+ BC. This is due to aberrant methylation along with 
differential ER-bound enhancer−promoter interactions [50].  
Enhancer of zeste homolog 2 (EZH2), an oncogenic histone methyltransferase, has a well- 
established role in the progression of aggressive cancers including BC. EZH2 has a critical role in 
connecting two critical epigenetic programs, it interacts directly with DNA methyltransferases and 
control DNA methylation functionally. Also, EZH2 is reported to be aberrantly activated in various 
forms of cancer including BC. The expression of EZH2 increased with various stages: lower in 
normal, and increased in atypia, ductal carcinoma in situ, invasive and metastatic BC samples [51, 
52]. Wherein, more aggressive BC and poor clinical outcome have been found to be associated 
with elevated EZH2 expression [51]. It has also been shown that Tamoxifen resistance in BC cells 
is driven by epigenetic reprogramming as a result of aberrant expression of EZH2 mediated the 









Furthermore, deregulation of DNA methylation mediated trastuzumab resistance in HER2+ BC 
via epigenetic reprogramming and suppression of TGFBI, CXCL2, and SLC38A1 genes 
suggesting that promoter hypermethylation of these genes could be of great therapeutic importance 
for HER2+ BC patients [54]. Inactivation of Spalt-like transcription factor 2 (SALL2) as a result 
of aberrant DNA methylation leads to tamoxifen resistance in BC via downregulation of ERα and 
PTEN. Thus, the use of DNMT inhibitor induces SALL2 upregulation to overcome tamoxifen 
resistance in BC cells which indicates the importance of co-therapy leading towards a better 
clinical outcome (Fig. 4) [55].  
Metabolic reprogramming, an important cancer hallmark is another major challenge, maintained 
by a number of signaling regulatory circuits affected and controlled by aberrant methylation or 
epigenetics.  It was recently discovered that methylation mediated metabolic reprogramming of a 
key glycolytic enzyme pyruvate kinase M2 (PKM2) by co-activator-associated arginine 
methyltransferase enhances BC cell energy, proliferation, migration and metastasis [56].  
Increasing evidence supported the role of DNA methylation and histone modifications in the 
progression of cancer as well as its role in chemoresistance which has garnered lot of attention 
[57]. Silencing of regulatory genes through hypermethylation supports uncontrolled cancer cell 
growth whereas hypomethylation causes activation of genes essential for metastasis and 
chemoresistance (Fig. 4) [58]. Various genes known to be involved in process of metabolizing 
drugs, repairing the cellular damage induced either by themselves or through any agents, play a 
pivotal role in drug resistance development [59]. For instance, Chekhun et al., 2007 analyzed the 
hypo- and hypermethylated DNA sequences and identified dysfunctional genes sequence involved 
in estrogen metabolism, apoptosis cell-cell contact and demonstrated that two opposing hypo- and 
hypermethylation processes may or may not enhance and complement each other in the disruption 
of pathways [60]. 
Poor or adverse survival outcomes have been found to be associated with DNMTs, histone lysine 
methyltransferases (HKMTs), protein arginine methyltransferases (PRMTs) PRMT 1, 3, 5, 7, 8, 
and histone lysine demethylase 2A (KDM2A) in BC (Fig. 4) [61-63]. Additionally, genome-wide 
analysis for breast tumor and adjacent tissues found increased levels of DNA methylation in ductal 
carcinoma to be related to the invasive form of BC and metastasis [64]. Hypermethylation of 
BRCA1 has been found to be associated with ER- BC and poor clinical outcomes [65]. Also, the 
epigenetic silencing of MSH2 through the hypermethylation of a promoter induced doxorubicin 
resistance in BC cells. Being reversible, these alterations may serve as targets to develop epigenetic 
therapies to re-sensitize doxorubicin-resistant BC cells (Fig. 4) [66]. A contrary relationship has 
been shown between methylation of the ERβ gene and tamoxifen resistance. Overall, there was 










Figure 4. Reversal of Epigenetics. The figure illustrates the studying of reversing the epigenetic 
alterations associated with poor clinical outcomes in BC using potential epigenetic biomarker and 
novel therapeutic pathways may lead to a successful anti-cancer treatment 
 
Epigenetic aberrations in tumor microenvironment (TME) have been reported in BC with 
implications of poor clinical outcome and drug resistance (Fig. 2). A study on AU565 and SKBR3, 
breast cancer cell lines, showed that CAF/Stromal secreted factors (such as cytokines, MMPs, and 
growth factors, TGF-β, miRNAs etc.) are actively involved in epigenetic pathways with 
subsequent upregulation of specific genes via DNA methylation patterns. This leads to 
reprogramming of cancer cell response to the TME locking in transcriptional changes that initiate 
them [68].  
On the other hand, a study on the influence of epigenome on PI3K signaling pathway reported that 
epigenetic regulator (KMT2D) is a key factor that leads to the inhibition of PI3K pathway leading 
to subsequent activation of ER dependent transcription. As such, this epigenetic change has been 
associated with higher tumor size reduction in mice models indicating the utility of epigenetic 
therapy in PIK3CA-mutant, ER-positive BC patients [69].  
A study on the characterization of specific DNA methylation profile in HER2 BCs observed a 
strong association between ER and PR gene methylation and expression [70]. The study postulated 









to low levels of functional ER and 17-β-estradiol metabolizing enzymes thus affecting anti-tumor 
activity of tamoxifen and producing a resistant phenotype. In addition to this, the study also 
reported that DNA methylation changes were apparent in the stroma of HER2+ cancers indicating 
the involvement of epigenetic imprints within the environment that facilitate tumor progression 
[71]. Another large-scale study observed distinct epigenetic changes in the microenvironment 
(epithelial, myoepithelial cells and stromal fibroblasts) of both normal breast tissues, in situ and 
invasive breast carcinomas. This indicates that epigenetic imprints in the microenvironment may 
drive aggressiveness and resistance in BC [72]. 
N6-methyladenosine (m6A) is the most prevalent deregulated methylation detected in the aberrant 
expression of cancer associated genes, drug resistance and stemness via modulating signaling 
mechanisms such as BRD4, MYC, SOCS2 and EGFR [73]. It was observed that m6A triggers BC 
pathogenesis via targeting apoptotic regulatory genes [74]. The over-expression of FTO (Fat mass 
and obesity-associated protein or alpha-ketoglutarate-dependent dioxygenase), a key m6A 
demethylase, triggers breast carcinogenesis by targeting BNIP3, a pro-apoptosis gene and tumor 
suppressor. Recently it has been shown a remarkable decreased m6A methylases (METTL3, 
METTL14 and WTAP) expression with a concomitant over expression of FTO in BC samples 
[75].  
Epigenetic modifications of stemness features of CSCs are often associated with disease 
progression and therapeutic failure. Hypoxia induced changes in methylation status, it induces 
ALKBH5 mediated demethylation and stabilization of NANOG, KLF4 mRNA crucial stemness 
proteins, leading to stemness of BC [76, 77]. This, critical growth and migration mechanism, 
indicates the critical role of epigenetic alterations due to m6A in progression of BC, hence m6A 
associated targets may be of great therapeutic importance for BC [78, 79]. 
2.2: Histone modifications 
Histone codes are referred to post translational changes in histone proteins. Changes in histone 
proteins introduce an additional level of multifaceted nature to phenotypes in cell [80]. Histone 
proteins are key elements of the nucleosome, which are accountable for keeping repressive 
chromatin in stable form. Histones are exceptionally alkaline, so they firmly bind with DNA, 
which is negatively charged by salt bridges and hydrogen bonds. The nucleosome is made of an 
octameric core having duplicate copies each of H2A, H2B, H3 and H4 histones wrapped by strands 
of DNA and a H1 linker histone. Repeating subunits of nucleosomes produce chromatin, which 
can possibly characterize the state in which hereditary data is organized inside a cell. Changes in 
conformational structure of chromatin present a specific positioning of the genome, in a dense or 
non-dense condition that regulates gene expression [81]. The structure of chromatin is changed by 
histone post translational modification, this caused by addition of chemical groups to the N-
terminal tails. The charge characteristics of histones are influenced by further groups added; as a 
result the structure of dense nucleosome is relaxed or closed.  
The above-mentioned moieties have the ability to bait more proteins which precisely identify the 
altered residues. As a result of this, environment of the chromatin is changed, due to which the 
access to the cis-regulatory elements is more restricted or relaxed.  
Alterations of histones can have enormous impact on processes related with DNA such as 
packaging, recombination, repair, replication, and transcription regulation. The most widely 









and enhancer regions [82]. These changes are regulated by numerous enzymes, for example, 
histone methyltransferases, demethylases, acetyltransferases, and deacetylases [83]. Other histone 
modifications include ubiquitination, phosphorylation, and other uncommon ones such as 
ADPribosylation, citrullination, formylation, deamination, propionylation, O-GlcNAcylation, 
butyrylation, proline isomerization, and crotonylation (Fig. 5) [84]. Changes at the chromatin level 
due to errors in post-translational changes in histone are called epimutations which may change 
gene expression patterns and give rise to a disease [85].  
It has been reported that histone acetylation modifications (HAMs) play significant role in BC 
tumorigenesis. Recent studies on aberrant HAMs aimed to reveal the initial molecular processes 
involved in the evolution of BC prognosis and treatment (Fig. 4) [86]. Xi et al. (2018), profiled 
histone modifications in BC using cell lines representing the five main molecular subtypes of BC. 
This study generated data defined subtype specific chromatin signatures which can serve as a 
reservoir for histone modification profiles in BC to nominate potential biomarkers with the 
possibility to find new personalized and targeted therapeutic for BC (Fig. 4) [87]. 
Elsheikh et al. investigated 880 human BC samples and documented that the differential levels of 
lysine acetylation (H3K9ac, H3K18ac, and H4K12ac), lysine (H3K4me2 and H4K20me3), and 
arginine methylation (H4R3me2) were observed in poorer prognostic BC subtypes, including basal 
and HER2+. Whereas hypoacetylation of H4K16ac is correlated with better clinical prognosis. 













Aberrant acetylation status is another critical epigenetic event related to reprogramming and 
modulation of gene expression implicated in BC pathogenesis, stemness metabolic reprogramming 
and resistance to therapeutics. Chemotherapy resistance is posing as one of the major clinical 
challenges in the management of BC. In line with this, an interesting finding shows that the 
accumulation of acetylated mitochondrial superoxide dismutase (SOD2) and mitochondrial 
reactive oxygen species (mtROS) enhance stem cell reprogramming in late stage of BC via 
promoting hypoxic signaling of hypoxia-induced factor 2α (HIF2α). Also, SOD2 acetylation 
provides BC cells with the ability to develop resistance against endocrine therapy (tamoxifen) via 
increasing peroxidase activity which is a well-established characteristic of CSC. This suggests that 
the acetylation of SOD2 might contribute by playing an effective role in more invasive, drug 
resistance and poor outcomes[89].  
Recent study findings showed that acetylation of the serine-arginine protein kinase 1 (SRPK1) is 
a key factor in the development of cisplatin resistance in BC cells. This may serve as a potential 
therapeutic opportunity to overcome the platinum related drug resistance [90]. 
Altered epigenetic changes via histone modifications molecules are critical in the pathogenesis and 
treatment of BC. Chatterjee et al. have reported that the use of resveratrol, a natural anticancer 
agent, restores the of expression of tumor suppressors by modulating epigenetic changes due to 
both methylation and acetylation at promoter of histone in BC cells [91].    
Deregulated chromatin alterations by histone modifiers modulate the expression of multiple genes 
associated with oncogenesis and development of cancer stemness features. Recently, it has been 
delineated that use of HDAC inhibitors suppressed the cancer stemness features in BC via 
inhibiting expression of super-enhancers (SEs) associated oncogenes [92].  
Generally, there are 18 potential enzymes of histone deacetylases (HDACs) grouped into four 
classes. In which HDAC class I (HDAC 1, 2, 3 and 8) seem to be the most important ones in 
carcinogenesis [93]. The use of HDAC inhibitors (HDACis) has showed promising outcomes in 
the attenuation of drug resistance in BC cells via targeting key efflux transporters, multidrug 
resistance protein 1 (MDR 1, ABCB1, P-glycoprotein) and BC resistance protein (BCRP, ABCG2) 
(Fig. 4) [94]. Worth mentioning, another study reported the role of epigenetic alterations as a prime 
cause of radio-resistance in BC cells. This caused by altered activities, high HDAC and low histone 
acetyl transferase (HAT), leading to suppressed or loss of histone phospho-acetylation and 
chromatin condensation. The variation of HDAC activity among BC patients suggests the 
implementation of a prior assessment of patients’ epigenome to maximize the benefit of HDAC 
inhibitor–based radio-sensitization [95].  
The expression of HDAC 1 and HDAC 6 have been studied in BC subtypes and show that the 
highest expression was observed in luminal A and Luminal B subtypes respectively [96, 97]. Thus, 
the expression of HDAC 1 and 6 are good prognostic factors and are positively associated with 
better therapeutic outcomes in ER+ BC [98]. Whereas the higher expression of class I HDAC2 
and 3 were associated with highly aggressive (ER-/PR-) BC subtypes. Moreover, declined survival 
in ER+ BC subtype has been associated with the elevated expression of class II a HDACs [99]. 
Lapierre et al. revealed that a significantly high expression of class II a (HDAC9) in basal subtype 
of BC was associated with the expression of SOX9 and poor prognosis of BC [100].  
Lysine-specific demethylase 1 (LSD1), a histone methylation eraser, is highly expressed in BC 









expression is directly correlated with the progression of BC and was found to be highly expressed 
in ER-/PR- BC subtypes [102, 103]. Similarly, EZH2 is reported to be aberrantly activated in 
various forms of cancer including breast cancer and is associated with aggressive form of breast 
cancer [51]. The reduction of CAF related histone mark, H3K27me3, leading to decreased 
expression of methyltransferase (EZH2) and subsequent upregulation of thrombospondin type 1 
motif 1 has been associated with tumor invasiveness in BC [104].  
Although tumorigenic role of histone proteins alterations is well discussed, adding to this it has 
recently been explored that interaction of pygopus 2 (Pygo2), a co-activator of Wnt/β-catenin 
signaling, with bi- or trimethylated lysine 4 of histone-3 is critical for BC development and 
metastasis and thus interfering pygo2- H3K4me2/3 interaction could be an important therapeutic 
option in BC management [105]. Furthermore, epigenetic alterations due to deregulated expression 
of LSD1 are also associated with reprogramming in BC stem cells stemness features [106]. 
Interestingly, a recent study shows that histone demethylase KDM7A, is critical for the growth 
and maintenance of BCSCs via upregulating the stemness-associated factors KLF4, c-MYC and 
BCL2 [107].  
Epigenetic reprogramming affects epithelial–mesenchymal transition (EMT), critical for cancer 
metastasis and drug resistance, through modulating the HDACs, TET2 hydroxylase along with 
Mbd3/NuRD complex eventually making cancer cells in a highly metastatic mesenchymal state 
and hence suggesting combinatorial interference may be efficient in suppressing BC metastasis 
[108].  
Increased expression of Nicotinamide N-methyltransferase (NNMT) is often correlated with poor 
clinical outcome and resistance in BC patients. The underlying mechanism includes stabilization 
of SIRT1, a deacetylation enzyme and its inhibition overcome resistance to adriamycin and 
paclitaxel in BC cells [109]. Poor prognosis in BC has been shown to be associated with the 
expression of histone acetyltransferases (GTF3C4 and NCOA3) [61]. Additionally, it has been 
shown that in BC cells, p300/CBP (CREB binding protein), which is a transcriptional coactivator 
of BRCA1, facilitate crosstalk between ER and NF-kB signaling pathways [110]. Moreover, it 
epigenetically induces EMT in breast metastasis by cooperating with DOT1L-cMyc complex. The 
acquisition of cancer stem cell-like properties in breast carcinogenesis is associated with the 
elevated level of p300-DOT1L-cMyc [111].  
2.3: Noncoding RNA processing 
In eukaryotic cells, a large portion of the genome is transcribed but not translated. It is well known 
that 2-3 % codes for proteins while 80 % is non-coding RNA [112, 113]. Non-coding RNAs can 
be categorized into small and long non-coding RNAs based on their molecular lengths. Small non-
coding RNAs are less than 200 nucleotides and may further classified into microRNA, piwi-
interacting RNA, small nuclear RNA, and small-interfering RNA. The best described small non-
coding RNAs in cancers are microRNAs, which obstruct protein syntheses either by cleaving 
mRNA or inhibition of translation [114].  
The non-coding RNAs whose length is more than 200 nucleotides are categorized as long non-
coding RNAs (lncRNAs). They control expression of gene both in cis and trans mechanisms. In 
cis mechanism, they are located in vicinity of target gene in the genome to repress gene expression 
by transcriptional interference in which the initiation of adjacent transcription is suppressed due to 








of gene in cis by attaching close to regulator DNA sequences and causing either to break 
preinitiation complex or overlay chromatin region [116, 117]. In trans mechanism, the lncRNAs 
control gene expression by interacting with epigenetic regulators, transcription factors, and RNA 
polymerases in which they may change localization or enzymatic functions of proteins [118-120].  
Recently, non-coding RNAs (ncRNAs) were reported for their contribution in a number of 
epigenetic processes controlling gene expression such as regulation of transcription, post 
transcriptional modification, and modulation of chromatin structure [121]. Current studies are 
focusing on the role of ncRNA in BC [122-125]. Recently, a study described and confirmed six 
lncRNAs markers in luminal BC subtype that remarkably enhanced its prognosis and possible 
therapeutic aims [126]. Another study investigated the role of FLVCR1-AS1 lnc RNA in BC and 
reported its role in tumorigenesis process with its value as a possible therapeutic target [127]. 
It has been reported that tumor invasiveness in BC is associated with the high expression of 
lncRNA HOTAIR [128, 129]. It has been shown that lncRNA-ATB activated by TGF-β induced 
Trastuzumab resistance in BC cells by upregulating ZEB1 and ZNF-217 and competitively binding 
miR-200c to induce EMT [130]. It has also reported that paclitaxel resistance is induced due to the 
high expression of lncRNA H19 leading to inhibit the transcription of pro-apoptotic genes BIK 
and NOXA [131].  
Recently it was shown that lncRNA DANCR (differentiation antagonizing nonprotein coding 
RNA) has role in inflammatory BC related phenomenon: inflammation-mediated EMT, and cancer 
stemness in late-stage TNBC. The investigators also showed that SOCS3 was downregulated by 
lncRNA DANCR with the help of EZH2 epigenetic mechanism [132]. It has also been shown that 
lnc RNA cancer susceptibility candidate 9 (CASC9) binds to EZH2 and regulate the MDR1 gene 
to result in drug-resistant BC [133]. 
Micro-RNA controls expressions of various genes either through suppression of the translational 
process or through degradation process. For instance, chemosensitivity of MCF-7 cells towards 
doxorubicin were increased by downregulating MDR-1 by miR-451 and MRP-1 by miR-326 
[134]. Ectopic expressions of miRNA 221 and miRNA 222 by inhibiting p27 (Kip1) transformed 
MCF-7 cells from hormone sensitive to a resistant cell line thus indicating that miRNAs supports 
growth of cancer cells even in absence of estrogen and support resistance towards endocrine 
therapy [135]. Similarly, miR-873, Let-7b/Let-7i also rendered resistance to tamoxifen treatment 
through inhibiting ERα and p27Kip1 [136]. MiR-129-5p by modulating EMT and through 
inhibition of ATP-binding cassette subfamily B member 1 (ABCB1), MDR can be reversed [137]. 
Similarly, by suppression TUBB3, ZEB1 and ZEB2 by miR-200c cancer cells were 
chemosensitised to paclitaxel treatment [138]. Whereas through downregulating Bcl-2 antagonist 
killer 1 (Bak1), MiR-125b supported drug resistance to paclitaxel [139]. Targeting of BRCA1 
helped miR-218 to increase sensitivity of breast cancer cells towards cisplatin [136, 140].  
CAF secreted soluble factors are also known to activate growth factor dependent-MAPK signaling 
in BC. As such, changes in these signaling pathways can also manipulate the expression of 
microRNAs (miRNAs). A study on BC was able to identify a novel CAF secreted miRNA 
signature known as hMAPK-miRNAs miR-221/222. This hMAPK-miRNA signature was 
observed to induce ER repression in ER-positive cell lines via paracrine interactions within the 









3: Recent research findings converge on promising diagnostic and therapeutic role of 
epigenetics in breast cancer 
BC is the most prevalent cancer in females with high morbidity and mortality rates worldwide. 
Within the last decade, the rates have jumped by more than 20% and 14% respectively [142]. 
Mammography is a gold-standard screening tool for BC diagnosis; however, it has significant 
limitations due to the lack of sensitivity and specificity in BC size of < 1cm which lead to 
misdiagnosis, overdiagnosis and/or overtreatment [143]. Successful management of this disease is 
based on the early detection of BC patients followed by a targeted treatment which can improve 
the 5-year survival rate by up to >93%. Consequently, an inaccurate diagnosis affects the patient 
negatively and results in unfavorable clinical outcomes. 
Currently, an early diagnosis of BC remains one of the greatest challenges. This highlights the 
need for the development and establishment of a robust and accurate diagnostic tool to screen, 
detect and monitor the progression of this disease [144]. Thus, establishing novel diagnostic and 
prognostic biomarkers will facilitate the early detection of this disease which provides better 
opportunities in the prevention and management of BC, leading to a major shift in the reduction 
of mortality and morbidity of BC worldwide [145].  
Herein, we focus on the current state of this discipline and emphasize the role of epigenetics as 
potential biomarkers for detection, prognostication and/or prediction of BC treatment efficacy. 
This section also reviews a crucial element of future targeted cancer therapy by describing the 
potential use of epigenetic modifiers in the prevention and treatment of BC. 
3.1: Significance of using epigenetic alterations as diagnostic, prognostic, and predictive 
biomarkers in Breast Cancer 
A biomarker is a measurable biochemical particle that can be found in tissues, blood, or body fluids 
in response to disease development and progression. This includes DNA, RNA, protein, or an 
epigenetic modification. An accurate tumor biomarker indicates the presence, assesses prognosis, 
and even guides targeted therapy of cancer [146].  
Carcinogenesis is a complex multistep process involving both genetic and epigenetic changes that 
generate multiple changes in gene expression which lead to an altered regulation of the cell cycle 
[147]. Epigenetic alteration, such as aberrant DNA methylation and histone acetylation at the 
promoter regions of genes, is one of the initial events in the cancer inducing mechanism as it 
contributes to the silencing of distinct genes (such as proapoptotic, cell cycle-inhibitor or DNA 
repair genes). It has been reported that the number of aberrantly methylated genes identified in BC 
is increasing rapidly [148]. Aberrant DNA methylation is considered as an attractive biomarker to 
be examined in liquid biopsies for many reasons; its early onset, cancer specificity, biological 
stability, and availability in bodily fluids. Being relatively highly stable and detectable in 
circulating cell-free tumor DNA (ccfDNA) from liquid biopsies, this enables the possibility of 
implementing DNA methylation as a fast, reliable, cost-effective and non-invasive testing of BC 
[146, 149-151]. 
It is well evident that aberrant DNA methylation plays a key role in breast tumorigenesis and drug 
resistance. Furthermore, it has been shown that the alteration of the DNA methylation profile of 
BC patient blood arises years before the cancer is clinically detected [152]. Consequently, aberrant 









As shown in Table 1, several studies have been conducted towards uncovering accurate epigenetic 
based biomarkers with high sensitivity and specificity. For instance, hypermethylation of 
hyaluronoglucosaminidase 2 (HYAL2) in blood can be detected in the very early stage of BC 
cases. This suggests that the HYAL2 methylation level can be used as an early marker to detect 
BC with great sensitivity and specificity of 64% and 90% respectively [154]. On the other hand, 
secretoglobin family 3A member 1 (SCGB3A1) did not distinguish cancerous cases from controls 
[151].  
Due to the inter/intratumoral heterogenicity of BC, it has been indicated that the use of one 
epigenetic biomarker for the detection of BC might be specific for one subtype and possibly will 
not serve for another which leads to false diagnosis. Consequently, a couple of gene panels were 
developed and evaluated to improve the sensitivity of BC detection. For instance, a two gene panel, 
RARβ and RASSF1A, was assessed by Kim et al., 2010 which reported the detection of BC with 
a significant sensitivity and specificity of 94.1% and 88.8% respectively [155]. Similarly, a six-
methylated-gene panel consisting of (SFN, P16, hMLH1, HOXD13, PCDHGB7 and RASSF1A) 
and three gene panel (APC, FOXA1 & RASSF1A) were able to detect BC in serum with a high 
level of sensitivity and specificity [156, 151].  
Additionally, novel DNA methylation markers, PRAC2, TDR10 and TMEM132C, were identified 
as potential diagnostic and prognostic markers due to their high expression in breast tumor tissue 
specifically in ER-positive patients [157]. Moreover, Nandy et al. proposed the use of five panel 
histone epigenetic biomarker (APLF, HJURP, MacroH2A.1, ɣH2AX, & H2Bub1) to serve as a 
potential prognostic biomarker to detect the probability of developing metastasis of BC [158]. 
Epigenetic characteristics of BC can also be determined using ctDNA analysis for early detection 
and targeted therapy of BC [159]. Agostini and colleagues reported identifying the ALU247 
methylation in BC patients using the MethyLight® method with greater than 99% sensitivity and 
69% specificity [160]. Liu et al examined the level of FHIT promoter methylation in serum and 
showed it was significantly associated with ductal breast carcinoma; this may be useful for the 
early diagnosis of this type of BC [161]. The three gene-panel of [Adenomatosis polyposis coli 
(APC), Fork-head box A1 (FOXA1) and Ras association domain family 1 isoform A (RASSF1A)] 
hypermethylation in ccfDNA was able to identify BC with sensitivity, specificity and accuracy 
higher than 75% [151].  
The epigenetic biomarkers can be useful as predictive markers to predict therapeutic drug 
responses [162]. Examples include the methylation of KEAP1 gene which was linked with a better 
overall survival; this might serve as a biomarker that suggests resistance to chemotherapy regimens 
involving taxanes [163]. It has also been shown that p16 promoter hypermethylation in BC 
suggested that p16 may be used as a prognostic and predictive marker to predict treatment response 
to hormonal therapy [164]. Besides, hypermethylation of p16 is significantly linked with a 
candidate pre-cancerous hypermethylation profile (BRCA1, BRCA2, ERα, and RARβ2). This 
suggests that p16 promoter hypermethylation of candidate genes could be detectable in early stages 
before pathological changes; this could be used to diagnose females who should be closely 
monitored for BC [165].  
DNA methylation of ESR1 in plasma cctDNA samples is significantly linked with the lack of 
estrogen receptor (ER) expression in excised tumors which is associated with lack of response to 








for endocrine treatment efficacy [167, 168]. The association between BRCA1 hypermethylation 
and increased sensitivity to platinum-based chemotherapy in ovarian and BC can also be utilized 
to implement BRCA1 as a predictor response biomarker to platin-based chemotherapy in BC 
patients [161, 169]. 




The blood-based test for BC biomarkers was approved by the Food and Drug Administration 
(FDA). Several cancer antigen biomarkers such as CA15-3, CA27.29, CA-125, CEA 
(carcinoembryonic antigen) and CTCs are exclusively recommended as prognostic markers to 
monitor treatment efficacy and disease relapse, rather than early diagnostic markers. Currently, 
mutation analysis screening test using gene mutation markers (BRCA1 and BRCA2) is the only 
used test for screening of hereditary BC [34]. Additionally, the currently used molecular In-Vitro 
Diagnostics (IVDs) include tumor profiling tools such as Prosigna, Mammaprint, OncotypeDX, 
and Endopredict which are based on gene expression and mutational profiles using conventional 
tissue biopsies and not DNA methylation. Oncotype DX is the most used one and designed for 
patients with ER+/HER2- and LN- primary BC. EndoPredict is a new predictive tool based on the 
analysis the expression of 8 targeted genes to estimate the risk of distant recurrence in BC patients 
with ER+/HER2- [172]. These cancer profiling tools were developed aiming to categorize BC 
patients into risk/treatment groups to assist in adjuvant treatment decision. However, their efficacy 
in clinical practice is limited to certain BC subtypes and therefore their implementation remains 
restricted.  
Currently, DNA methylation markers are not yet implemented in the clinical setting of BC 
detection. However, the prognostic value of these markers was utilized to develop a reliable PCR 
based prognostic assay for BC. In 2018, Qiagen and Therawis introduced the first clinically 
validated DNA methylation-based assay, therascreen® PITX2 RGQ. This predictive IVD is 
available in Europe to predict the response of certain high-risk BC patients (ER+/HER2- and LN+) 
to anthracycline-based chemotherapy with or without endocrine therapy. Hence, the use of 
therascreen® PITX2 RGQ is limited as this test is not beneficial for patients with more aggressive 
and/or resistant subtypes such as HER2+, TNBC or BC with lymph node involvement [173]. 
Besides, IvyGene is a validated DNA methylation-based test in the USA which is used to detect 
early stage of four common cancers including BC (breast, colon, liver and lung). The use of a panel 
of 46 markers is able to quantify the presence of these cancers using blood samples from cancer 
suspected patients. 
3.2: Utilizing epigenetic modifying drugs as a therapeutic approach in BC  
As mentioned earlier, in cancer cells, gene alterations can result from both mutations and/or 
through epigenetic modifications to chromosomes that change gene expression patterns. 
Epigenetic modifications, unlike genetic mutations, include abnormal cytosine DNA methylation 
and histone hypoacetylation in the promoter region of important genes and are generally reversible. 
Hence, restoring normal growth phenotype is theoretically possible through implementing 
epigenetic modifying drugs to reverse aberrant epigenetic alterations and this appears to be a 









Accumulating evidence suggests that epigenetic therapies could potentially work synergistically, 
when combined together and/or with conventional chemotherapy, in increasing therapeutic effects. 
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treatment have been tested in various trials to evaluate the efficacy of these drugs to overcome 
epigenetic alterations and hormone resistance [176].  
Molecules listed in Table 2 include some of the potential epigenetic drugs for BC treatment 
including previously FDA approved and investigational epigenetic drugs (DNMT and HDAC 
inhibitors). For instance, azacitidine and decitabine (cytidine analogs), are approved DNTM 
inhibitors which can induce DNA demethylation. Also, vorinostat, panobinostat, belinostat, and 
romidepsin are FDA-approved HDAC inhibitors.  
Table.2: list of potential investigational and approved epigenetic drugs for BC therapy 
 
Several clinical studies have investigated using a combination of epigenetic modifiers (Table 2) 
and shown promising anticancer effects against breast carcinoma. They also reported positive 
results in favor of combined epigenetic drugs with/without anticancer therapy over the use of 
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single-agent therapy. For instance, phase I and II clinical trials have been conducted using HDAC 
inhibitors (vorinostat, panobinostat and entinostat) alone or in combination with other therapeutic 
agents such as endocrine therapy, immunotherapy and/or chemotherapy [177]. The results from 
terminated or completed trials ranged from no response to 55% response [176]. 
In 2016, Li and his colleagues implied that the extensive expression of histone deacetylase enzyme 
5 (HDAC5) in human BC tissues indicates that HDAC5 may serve as a potential novel prognostic 
marker and selective therapeutic target for BC [178]. Histone deacetylase enzymes 1 and 3 
(HDAC1 and HDAC3) are also highly expressed in BC. In Vitro studies showed that the exposures 
of breast carcinoma cells to HDAC1 inhibitors (vorinostat or entinostat) reverse the immune 
evasion to enhance the sensitivity to T-cell-mediated lysis [179, 180]. Moreover, several HDACis 
have indicated therapeutic effects against triple negative breast cancer (TNBC) such as vorinostat, 
sodium butyrate, mocetinostat, panobinostat, entinostat, YCW1 and N-(2-hydroxyphenyl)-2-
propylpentanamide [181]. 
HDAC inhibitors (HDACis) have also shown limited effect as single agents. Conversely, in 
combination with other anticancer agents, HDACis demonstrated promising therapeutic results. 
For instance, LMK-235 is a promising new HDAC5 inhibitor, providing a novel therapeutic 
strategy for BC treatment in combination with bortezomib [178]. Additionally, the combination of 
HDAC inhibitor (Vorinostat) and endocrine therapy (Tamoxifen) showed significant reversal of 
hormone resistance in ER- positive advanced metastatic BC patients [182].  
Potential epi-drug molecules listed in Table 2 have shown promising anticancer effects against 
breast carcinoma. Promising phase I clinical data have robustly demonstrated that the combination 
of epigenetic therapies of DNMT and HDAC inhibitors (5-fluoro-2′-deoxycytidine and 
tetrahydrouridine) was well tolerated. It also reported that this combination has the potential to 
overcome chemotherapy resistance and partial response of 16 months in a BC patient [183]. 
Consequently, a phase II clinical study was conducted to assess response to this combination in 
patients with advanced BC. Efficacy results of the DNMT and HDAC inhibitors combination 
suggest that further testing of these drugs is unwarranted in BC [184]. On the other hand, Connolly 
et al., 2017 reported results from phase II clinical trial, investigated the implementing of combined 
epigenetic therapies, DNMT and HDAC inhibitors (5-azacitidine (Azacitidine) and entinostat). 
Finding from this study suggests that some women with advanced hormone-resistant BC may 
benefit from epigenetic therapy and/or reintroduction of endocrine therapy beyond progression 
[185] 
Currently, implementing epigenetic therapies for BC are still in the early stages and have not 
moved into routine clinical practice. The investigated DNMT and/or HDAC inhibitors (single 
and/or combined therapies) have shown encouraging results in BC treatment, nevertheless, these 
drugs are relatively toxic, and their pharmacodynamics remain nonspecific as gene modulators 
which consider as major challenges. Also, there are additional limitations which restrict the use of 
these epigenetic alterations as diagnostic, prognostic biomarker and therapeutic agents. These 
include the conflicted results due to the use of variable methodologies across different studies, the 
low load of epigenetic substance in the specimens, and the necessity to enhance purification 
methods of histone and non-coding RNA. Finally, the epigenetic modifications are usually cell 
specific which may be directly impacted by external factors such as environment and aging. As a 









consideration when selecting epigenetic alteration as a possible cancer specific biomarker [165, 
186, 187].  
 
4: Conclusion 
Evidently, epigenetic alterations play an important role in the pathogenesis and poor clinical 
outcomes of BC via various mechanisms. Consequently, several methylated genes and potential 
epigenetics inhibitors have been studied and proposed as promising diagnostic, prognostic, and 
therapeutic agents for BC. A number of studies have reported the feasibility of using methylated 
genes as potential biomarkers for BC. Nevertheless, currently only two DNA methylation-based 
assays were developed and validated as prognostic/predictive and diagnostic CE-IVD in the EU 
and USA (the therascreen® PITX2 RQG and IvyGene respectively). 
Apart from this, accumulating evidence suggests that epigenetic therapies could potentially work 
synergistically, when combined together and/or with conventional chemotherapy, in increasing 
therapeutic effects. Yet, the findings are not satisfactory and their validation and transfer to the 
clinical setting is still outstanding. Consequently, this emphasizes the need for further 
investigations to carefully assess the clinical benefits from implementing these markers. Besides, 
further clinical trials are necessary to precisely assess and validate the effects of epigenetic 
modifiers molecules in the treatment of BC. This will facilitate the development of novel reliable 
biomarkers and effective targeted treatments leading to lower incidence and better management of 
BC. 
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MeCP2 Methyl-CpG-binding protein 2 
H3 Histone 3 
H4 Histone 4 
TNBC Triple negative breast cancer 
ERα Estrogen receptor α 
PTEN Phosphatase and tensin homolog 
ERβ Estrogen receptor beta 









MMPs Matrix metallopeptidases 
TGF-β Transforming growth factor-β 
KMT2D Lysine methyltransferase 2D 
HDAC Histone deacetylases 
KDM7A Lysine demethylase 7A 
BCSCs Breast cancer stem cells 
ctDNA Cell-free tumor DNA 
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